• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by T2 Biosystems Inc.

    4/19/24 4:31:27 PM ET
    $TTOO
    Medical/Dental Instruments
    Health Care
    Get the next $TTOO alert in real time by email
    SC 13D 1 d830497dsc13d.htm SC 13D SC 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. __)*

     

     

    T2 Biosystems, Inc.

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    89853L302

    (CUSIP Number)

    Andrei Dorenbaum

    c/o CR Group L.P.

    1000 Main Street, Suite 2500

    Houston, TX 77002

    (703) 209-7350

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    April 12, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☒

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section of the Exchange Act but shall be subject to all other provisions of the Exchange Act (however, see the Notes).

     

     

     


    CUSIP No. 89853L302       Page 2 of 13

     

     1.    

     Names of Reporting Persons

     

     Nathan D. Hukill

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     

     (a) ☒ (1)  (b) ☐

     3.  

     SEC Use Only

     

     4.  

     Source of Funds (See Instructions)

     

     OO (2)

     5.  

     Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     United States

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.     

     Sole Voting Power

     

     0

        8.   

     Shared Voting Power

     

     4,104,838

        9.   

     Sole Dispositive Power

     

     0

       10.   

     Shared Dispositive Power

     

     4,104,838

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     4,104,838

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     46.68% (3)

    14.  

     Type of Reporting Person (See Instructions)

     

     IN

     

    (1)

    Nathan D. Hukill, CR Group L.P., CRG Partners III L.P., CRG Partners III – Parallel Fund “A” L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P., and CRG Partners III Parallel Fund “B” (Cayman) L.P. are members of a group for the purposes of this Schedule 13D.

    (2)

    The shares of the Common Stock of the Issuer were acquired in exchange for and satisfaction of such partial debt cancellation of certain loans outstanding held by the group.

    (3)

    This percentage is calculated based on 8,792,950 shares of Common Stock issued and outstanding as of April 12, 2024, as provided by the Issuer. Does not include 1,716,048 shares of Common Stock issuable upon conversion of Series A Convertible Preferred Stock and 108,752 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock. The shares of Series A Convertible Preferred Stock and the shares of Series B Convertible Preferred Stock are held by CRG Partners III Parallel Fund “B” (Cayman) L.P. and the conversion of which are subject to beneficial ownership limitations.


    CUSIP No. 89853L302       Page 3 of 13

     

     1.    

     Names of Reporting Persons

     

     CR Group L.P.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     

     (a) ☒ (1)  (b) ☐

     3.  

     SEC Use Only

     

     4.  

     Source of Funds (See Instructions)

     

     OO (2)

     5.  

     Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.     

     Sole Voting Power

     

     0

        8.   

     Shared Voting Power

     

     4,104,838

        9.   

     Sole Dispositive Power

     

     0

       10.   

     Shared Dispositive Power

     

     4,104,838

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     4,104,838

    12.  

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     46.68% (3)

    14.  

     Type of Reporting Person (See Instructions)

     

     IA

     

    (1)

    Nathan D. Hukill, CR Group L.P., CRG Partners III L.P., CRG Partners III – Parallel Fund “A” L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P., and CRG Partners III Parallel Fund “B” (Cayman) L.P. are members of a group for the purposes of this Schedule 13D..

    (2)

    The shares of the Common Stock of the Issuer were acquired in exchange for and satisfaction of such partial debt cancellation of certain loans outstanding held by the group.

    (3)

    This percentage is calculated based on 8,792,950 shares of Common Stock issued and outstanding as of April 12, 2024, as provided by the Issuer. Does not include 1,716,048 shares of Common Stock issuable upon conversion of Series A Convertible Preferred Stock and 108,752 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock. The shares of Series A Convertible Preferred Stock and the shares of Series B Convertible Preferred Stock are held by CRG Partners III Parallel Fund “B” (Cayman) L.P. and the conversion of which are subject to beneficial ownership limitations.


    CUSIP No. 89853L302       Page 4 of 13

     

     1.    

     Names of Reporting Persons

     

     CRG Partners III L.P.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     

     (a) ☒ (1)  (b) ☐

     3.  

     SEC Use Only

     

     4.  

     Source of Funds (See Instructions)

     

     OO (2)

     5.  

     Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.     

     Sole Voting Power

     

     0

        8.   

     Shared Voting Power

     

     682,036

        9.   

     Sole Dispositive Power

     

     0

       10.   

     Shared Dispositive Power

     

     682,036

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     682,036

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     7.76% (3)

    14.  

     Type of Reporting Person (See Instructions)

     

     PN

     

    (1)

    Nathan D. Hukill, CR Group L.P., CRG Partners III L.P., CRG Partners III – Parallel Fund “A” L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P., and CRG Partners III Parallel Fund “B” (Cayman) L.P. are members of a group for the purposes of this Schedule 13D.

    (2)

    The shares of the Common Stock of the Issuer were acquired in exchange for and satisfaction of such partial debt cancellation of certain loans outstanding held by the group.

    (3)

    This percentage is calculated based on 8,792,950 shares of Common Stock issued and outstanding as of April 12, 2024, as provided by the Issuer.


    CUSIP No. 89853L302       Page 5 of 13

     

     1.    

     Names of Reporting Persons

     

     CRG Partners III – Parallel Fund “A” L.P.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     

     (a) ☒ (1)  (b) ☐

     3.  

     SEC Use Only

     

     4.  

     Source of Funds (See Instructions)

     

     OO (2)

     5.  

     Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.     

     Sole Voting Power

     

     0

        8.   

     Shared Voting Power

     

     424,716

        9.   

     Sole Dispositive Power

     

     0

       10.   

     Shared Dispositive Power

     

     424,716

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     424,716

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     4.83% (3)

    14.  

     Type of Reporting Person (See Instructions)

     

     PN

     

    (1)

    Nathan D. Hukill, CR Group L.P., CRG Partners III L.P., CRG Partners III – Parallel Fund “A” L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P., and CRG Partners III Parallel Fund “B” (Cayman) L.P. are members of a group for the purposes of this Schedule 13D.

    (2)

    The shares of the Common Stock of the Issuer were acquired in exchange for and satisfaction of such partial debt cancellation of certain loans outstanding held by the group.

    (3)

    This percentage is calculated based on 8,792,950 shares of Common Stock issued and outstanding as of April 12, 2024, as provided by the Issuer.


    CUSIP No. 89853L302       Page 6 of 13

     

     1.    

     Names of Reporting Persons

     

     CRG Partners III (Cayman) Unlev AIV I L.P.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     

     (a) ☒ (1)  (b) ☐

     3.  

     SEC Use Only

     

     4.  

     Source of Funds (See Instructions)

     

     OO (2)

     5.  

     Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     Cayman Islands

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.     

     Sole Voting Power

     

     0

        8.   

     Shared Voting Power

     

     136,409

        9.   

     Sole Dispositive Power

     

     0

       10.   

     Shared Dispositive Power

     

     136,409

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     136,409

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     1.55% (3)

    14.  

     Type of Reporting Person (See Instructions)

     

     PN

     

    (1)

    Nathan D. Hukill, CR Group L.P., CRG Partners III L.P., CRG Partners III – Parallel Fund “A” L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P., and CRG Partners III Parallel Fund “B” (Cayman) L.P. are members of a group for the purposes of this Schedule 13D.

    (2)

    The shares of the Common Stock of the Issuer were acquired in exchange for and satisfaction of such partial debt cancellation of certain loans outstanding held by the group.

    (3)

    This percentage is calculated based on 8,792,950 shares of Common Stock issued and outstanding as of April 12, 2024, as provided by the Issuer.


    CUSIP No. 89853L302       Page 7 of 13

     

     1.    

     Names of Reporting Persons

     

     CRG Partners III (Cayman) Lev AIV I L.P.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     

     (a) ☒ (1)  (b) ☐

     3.  

     SEC Use Only

     

     4.  

     Source of Funds (See Instructions)

     

     OO (2)

     5.  

     Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     United States

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.     

     Sole Voting Power

     

     0

        8.   

     Shared Voting Power

     

     1,983,262

        9.   

     Sole Dispositive Power

     

     0

       10.   

     Shared Dispositive Power

     

     1,983,262

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     1,983,262

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     22.56% (3)

    14.  

     Type of Reporting Person (See Instructions)

     

     PN

     

    (1)

    Nathan D. Hukill, CR Group L.P., CRG Partners III L.P., CRG Partners III – Parallel Fund “A” L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P., and CRG Partners III Parallel Fund “B” (Cayman) L.P. are members of a group for the purposes of this Schedule 13D.

    (2)

    The shares of the Common Stock of the Issuer were acquired in exchange for and satisfaction of such partial debt cancellation of certain loans outstanding held by the group.

    (3)

    This percentage is calculated based on 8,792,950 shares of Common Stock issued and outstanding as of April 12, 2024, as provided by the Issuer.


    CUSIP No. 89853L302       Page 8 of 13

     

     1.    

     Names of Reporting Persons

     

     CRG Partners III Parallel Fund “B” (Cayman) L.P.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     

     (a) ☒ (1)  (b) ☐

     3.  

     SEC Use Only

     

     4.  

     Source of Funds (See Instructions)

     

     OO (2)

     5.  

     Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     United States

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.     

     Sole Voting Power

     

     0

        8.   

     Shared Voting Power

     

     878,415

        9.   

     Sole Dispositive Power

     

     0

       10.   

     Shared Dispositive Power

     

     878,415

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     878,415

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     9.99% (3)

    14.  

     Type of Reporting Person (See Instructions)

     

     PN

     

    (1)

    Nathan D. Hukill, CR Group L.P., CRG Partners III L.P., CRG Partners III – Parallel Fund “A” L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P., and CRG Partners III Parallel Fund “B” (Cayman) L.P. are members of a group for the purposes of this Schedule 13D.

    (2)

    The shares of the Common Stock of the Issuer were acquired in exchange for and satisfaction of such partial debt cancellation of certain loans outstanding held by the group.

    (3)

    This percentage is calculated based on 8,792,950 shares of Common Stock issued and outstanding as of April 12, 2024, as provided by the Issuer. Does not include 1,716,048 shares of Common Stock issuable upon conversion of Series A Convertible Preferred Stock and 108,752 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock. The shares of Series A Convertible Preferred Stock and the shares of Series B Convertible Preferred Stock are held by CRG Partners III Parallel Fund “B” (Cayman) L.P. and the conversion of which are subject to beneficial ownership limitations.


    CUSIP No. 89853L302       Page 9 of 13

     

    Explanatory Note

    The Reporting Persons (as defined in Item 2 below) previously reported beneficial ownership of the Common Stock (as defined in Item 1 below) of the Issuer (as defined in Item 1 below) in a statement (including amendments thereto) on Schedule 13G. The previous statement on Schedule 13G was filed pursuant to Rule 13d-1(c) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Reporting Persons’ beneficial ownership of Common Stock has been regularly reported and disclosed in Form 4s filed with the Securities and Exchange Commission (the “SEC”), when required. The Reporting Persons are now filing this statement on Schedule 13D (this “Schedule 13D”) because, as of April 12, 2024 (the “Trigger Acquisition Date”), the Reporting Persons had acquired beneficial ownership in excess of 20% of the outstanding Common Stock of the Issuer.

    Item 1. Security and Issuer

    This Schedule 13D relates to the common stock, par value $0.001 per share (the “Common Stock”), of T2 Biosystems, Inc., a Delaware corporation (the “Issuer”). The address of the principal executive offices of the Issuer is 101 Hartwell Avenue, Lexington, MA 02421.

    Item 2. Identity and Background

    This Schedule 13D is being filed jointly by each of the following persons (collectively, the “Reporting Persons”): Nathan D. Hukill (“Mr. Hukill”), a citizen of the United States, CR Group L.P., a Delaware limited partnership (“CR Group”), CRG Partners III – Parallel Fund “A” L.P., a Delaware limited partnership (“CRG Parallel Fund A”), CRG Partners III (Cayman) Unlev AIV I L.P., a Cayman Islands exempted limited partnership (“CRG Unlev AIV”), CRG Partners III (Cayman) Lev AIV I L.P., a Cayman Islands exempted limited partnership (“CRG Lev AIV”), and CRG Partners III Parallel Fund “B” (Cayman) L.P., a Cayman Islands exempted limited partnership (“CRG Parallel Fund B” and collectively with CRG Parallel Fund A, CRG Unlev AIV and CRG Lev AIV, the “CRG Funds”).

    The Reporting Persons have entered into an agreement of joint filing, a copy of which is attached hereto as Exhibit 99.1.

    CR Group is a registered investment adviser to the CRG Funds, which directly hold the shares of Common Stock to which this Schedule 13D relates for the benefit of their respective investors, and in such capacity CR Group has voting and dispositive power over such shares. CR Group is indirectly controlled by Mr. Hukill.

    The principal business address and principal office of Mr. Hukill, the CR Group and the CRG Funds is 1000 Main St., Suite 2500, Houston, Texas 77002. The principal business of CR Group and the CRG Funds is making healthcare-focused investments. The principal employment of Mr. Hukill is making healthcare-focused investments.

    During the last five years, none of the Reporting Persons has been (a) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (b) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction as a result of which proceeding such Reporting Person or person is or was subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

    Item 3. Source and Amount of Funds or Other Consideration

    The information set forth in Items 5 and 6 of this Schedule 13D is hereby incorporated by reference in its entirety into this Item 3.

    All of the shares reported on this Schedule 13D were acquired from the Issuer in exchange for the Reporting Persons’ cancellation of outstanding loans to the Issuer under that certain Term Loan Agreement, dated as of December 30, 2016, as amended, by and among the Issuer and CRG Servicing LLC, as administrative agent and collateral agent, and the lenders named therein. The most recent acquisition occurred on April 12, 2024. Refer to the Issuer’s current reports on Form 8-K filed on July 6, 2023, February 15, 2024 and April 18, 2024 for additional information.


    CUSIP No. 89853L302       Page 10 of 13

     

    Item 4. Purpose of Transaction

    The information set forth in Items 3 and 6 of this Schedule 13D is hereby incorporated by reference in its entirety into this Item 4.

    The Reporting Persons acquired beneficial ownership of the shares of Common Stock reported herein for investment purposes with the aim of increasing the value of their investment and the Issuer. The Reporting Persons intend to review their investment on a regular basis and, as a result thereof, may at any time or from time to time determine, either alone or as part of a group, (i) to acquire additional securities of the Issuer, through privately negotiated transactions with the Issuer or otherwise, or (ii) to dispose of all or a portion of the securities of the Issuer owned by them in the open market, in privately negotiated transactions, or otherwise

    Except as set forth in this Item 4, none of the Reporting Persons have a present plan or proposal that relates to or would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D of the Exchange Act.

    Item 5. Interest in Securities of the Issuer

    The information contained in rows 7, 8, 9, 10, 11 and 13 on each of the cover pages of this Schedule 13D and the information set forth or incorporated in Items 2 and 3 of this Schedule 13D is incorporated by reference in its entirety into this Item 5.

    By virtue of the relationships among the Reporting Persons described herein, the Reporting Persons may be deemed to constitute a group within the meaning of Section 13(d)(5) of the rules and regulations promulgated by the Securities and Exchange Commission pursuant to the Exchange Act. As such, pursuant to Rule 13d-3 under the Exchange Act, such group may be deemed to beneficially own an aggregate of 4,104,838 shares of Common Stock, representing in the aggregate approximately 46.68% of the issued and outstanding shares of Common Stock, as calculated pursuant to Rule 13d-3 under the Exchange Act.

    Except as set forth in this Schedule 13D, none of the Reporting Persons has effected any transactions in Common Stock during the last 60 days.

    No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, the shares of Common Stock beneficially owned by any of the Reporting Persons.

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

    The information set forth in Items 3 and 4 of this Schedule 13D is incorporated by reference in its entirety to this Item 6.

    Item 7. Material to be Filed as Exhibits

    Exhibit 99.1 Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.


    CUSIP No. 89853L302       Page 11 of 13

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: April 19, 2024

     

    Nathan D. Hukill

    /s/ Nathan D. Hukill

    An individual
    CR Group L.P.
    CRG Partners III L.P.
    CRG Partners III – Parallel Fund “A” L.P.
    CRG Partners III (Cayman) Unlev AIV I L.P.
    CRG Partners III (Cayman) Lev AIV I L.P.
    CRG Partners III Parallel Fund “B” (Cayman) L.P.
    By:  

    /s/ Nathan D. Hukill

      Nathan D. Hukill, authorized signatory


    CUSIP No. 89853L302       Page 12 of 13

     

    EXHIBITS

    Exhibit 99.1 Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.

    Get the next $TTOO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TTOO

    DatePrice TargetRatingAnalyst
    2/18/2022$0.70Neutral → Buy
    Alliance Global Partners
    More analyst ratings

    $TTOO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Liebman Seymour

      4 - T2 Biosystems, Inc. (0001492674) (Issuer)

      1/2/25 6:58:44 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Chief Commercial Officer Giffin Brett A.

      4 - T2 Biosystems, Inc. (0001492674) (Issuer)

      1/2/25 6:55:13 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Adams Laura Lee

      4 - T2 Biosystems, Inc. (0001492674) (Issuer)

      1/2/25 6:46:12 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care

    $TTOO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

      LEXINGTON, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financial and operational results for the fourth quarter and full year ended December 31, 2024. Full Year 2024 and Recent Commercial Highlights (unaudited) Achieved record product revenues of $2.3 million for the fourth quarter of 2024 and $8.3 million for the full-year 2024, representing increases of 37% and 23% respectively, compared to the prior year period, driven by record sepsis test sales.Executed contracts for 27 T2Dx® Instruments in 2024, including

      1/7/25 9:00:00 AM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European Distributor

      LEXINGTON, Mass., Dec. 18, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the sale of four T2Dx® Instruments to its European (EU) distributor that represents multiple EU counties, demonstrating commercial expansion and increased international market penetration. The multiple instrument sale demonstrates commercial expansion to enable increased utilization of the T2Bacteria® Panel, the T2Candida® Panel, and the T2Resistance® Panel. The target hospitals for the new instruments include: Selling a second T2Dx Instrument to a major reference hospital to expand "same st

      12/18/24 9:00:00 AM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally

      LEXINGTON, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has surpassed the shipment of 250,000 sepsis tests, marking a significant milestone that underscores the growing customer adoption of the Company's direct-from-whole-blood technology. A meta-analysis of 14 controlled studies, published in a peer-reviewed medical journal, compared T2 Biosystems' sepsis tests to blood culture-based diagnostics, and showed that T2 Biosystems' products provided: faster time to detection (e.g., species identification 77 hours faster), faster targeted therapy (

      12/17/24 9:00:00 AM ET
      $TTOO
      Medical/Dental Instruments
      Health Care

    $TTOO
    Leadership Updates

    Live Leadership Updates

    See more

    $TTOO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $TTOO
    SEC Filings

    See more
    • Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors

      Avacta Group plc Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors London, England; July 8, 2024; Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments and powerful diagnostics, today announced the appointment of Darlene Deptula-Hicks, MBA as a Non-Executive Director of the Company's Board of Directors, effective 26 June 2024. Ms. Deptula-Hicks is a highly accomplished financial executive with decades of experience working with and advising private and public life sciences companies. Shaun Chilton, Chairman of the Board of Avacta, commented: "Avacta is at a pivotal time in its e

      7/8/24 8:15:00 AM ET
      $PIRS
      $TTOO
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • T2 Biosystems Hires Industry Veteran Brett Giffin as Chief Commercial Officer

      LEXINGTON, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the appointment of Brett Giffin as its Chief Commercial Officer, effective November 8, 2021. As Chief Commercial Officer, Mr. Giffin will join the Company's executive leadership team and lead our commercial growth initiatives with direct responsibility for global sales, marketing, service, and customer support functions. Mr. Giffin replaces Anthony Pare, who recently accepted a role as CEO at BioPorto A/S. "We are thrilled to have Brett join T2 Biosystems as Chief Commercial Officer," said John Sperzel, Chairman and CEO at T2

      11/4/21 4:04:00 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • T2 Biosystems Appoints Laura Adams to Its Board of Directors

      LEXINGTON, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the appointment of Laura Adams to its Board of Directors, effective immediately. "We are excited to have Laura join the T2 Biosystems Board of Directors," said John Sperzel, Chairman and CEO at T2 Biosystems. "Her success as a healthcare delivery innovator has deep roots in understanding the critical threats posed by infections and sepsis. She will be a crucial asset to T2 Biosystems as we continue on our growth trajectory." Ms. Adams currently serves as Special Advisor at the National Academy of Medicine (NAM), providing lead

      10/19/21 4:05:00 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • T2 Biosystems upgraded by Alliance Global Partners with a new price target

      Alliance Global Partners upgraded T2 Biosystems from Neutral to Buy and set a new price target of $0.70

      2/18/22 10:16:52 AM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • Alliance Global Partners resumed coverage on T2 Biosystems with a new price target

      Alliance Global Partners resumed coverage of T2 Biosystems with a rating of Neutral and set a new price target of $1.65 from $2.40 previously

      3/5/21 7:31:44 AM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • T2 Biosystems downgraded by Alliance Global Partners with a new price target

      Alliance Global Partners downgraded T2 Biosystems from Buy to Neutral and set a new price target of $2.40 from $2.60 previously

      1/27/21 8:12:03 AM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • SEC Form 8-K filed by T2 Biosystems Inc.

      8-K - T2 Biosystems, Inc. (0001492674) (Filer)

      4/4/25 5:47:15 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • SEC Form NT 10-K filed by T2 Biosystems Inc.

      NT 10-K - T2 Biosystems, Inc. (0001492674) (Filer)

      4/1/25 9:00:30 AM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • SEC Form 8-K filed by T2 Biosystems Inc.

      8-K - T2 Biosystems, Inc. (0001492674) (Filer)

      2/20/25 9:00:24 AM ET
      $TTOO
      Medical/Dental Instruments
      Health Care

    $TTOO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by T2 Biosystems Inc.

      SC 13G - T2 Biosystems, Inc. (0001492674) (Subject)

      11/14/24 3:38:45 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by T2 Biosystems Inc.

      SC 13G - T2 Biosystems, Inc. (0001492674) (Subject)

      11/6/24 9:02:19 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by T2 Biosystems Inc.

      SC 13G - T2 Biosystems, Inc. (0001492674) (Subject)

      11/6/24 9:01:48 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care

    $TTOO
    Financials

    Live finance-specific insights

    See more
    • T2 Biosystems Announces Third Quarter 2024 Financial Results

      LEXINGTON, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced financial and operational results for the third quarter ended September 30, 2024. Recent Financial and Commercial Highlights Achieved third quarter total revenue of $2.0 million, representing an increase of 34% compared to the prior year period.Achieved sepsis test panel revenue of $1.4 million, representing an increase of 34% compared to the prior year period, driven by increased U.S. T2Bacteria® Panel revenue.Executed contracts for 11 T2Dx® Instruments during the third quar

      11/14/24 4:05:00 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • T2 Biosystems to Report Third Quarter 2024 Financial Results and Business Updates on November 14, 2024

      LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the third quarter 2024 and business updates after market close on Thursday, November 14, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the Events & Presentations section. To listen to the conference call, please dial 877-545-0320

      11/5/24 8:00:00 AM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • T2 Biosystems to Host Business Update Call on October 10, 2024

      LEXINGTON, Mass., Oct. 08, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will host a business update call to provide additional details on recent developments after market close at 4:30pm ET on Thursday October 10, 2024. On the call management also plans to address select questions from shareholders that can be submitted in advance to the investor relations team at [email protected]. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the

      10/8/24 4:05:00 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care